Constipation: Occurs in 3% to 5% of patients, compared to 1.5% on a placebo
Copper tripeptide-1 also possesses a powerful ability to protect cells through anticancer and anti-inflammatory actions
In addition, altered metabolism or metabolic rewiring facilitates the adaptation of cancer cells to changing external environments, and this adaptation may render certain nutrients indispensable, a process known as nutrient addiction [15]
Higher doses generally produce greater appetite suppression and weight loss, though individual response varies
Clinical trials demonstrate substantial weight loss: semaglutide (Wegovy) produced approximately 15% average body weight loss, while tirzepatide (Zepbound) produced approximately 20% average weight loss over 72 weeks
Inyectar por va subcutnea (en el abdomen o en la parte externa del muslo)